Inici › Síndromes mielodisplàsiques › Illinois › Chicago
Assaigs clínics de Síndromes mielodisplàsiques a Chicago, IL
13 estudis de Síndromes mielodisplàsiques busquen participants en centres de Chicago i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
ReclutantFase 2
- Northwestern University, Chicago
- Swedish Covenant Hospital, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
ReclutantFase 1
- University of Chicago Comprehensive Cancer Center, Chicago
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutantFase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- i 1 més
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
ReclutantFase 3
- University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutantFase 1/2
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Reclutant
- Northwestern University Feinberg School of Medicine, Chicago
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
ReclutantFase 2
- University of Illinois Cancer Center, Chicago
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
ReclutantFase 1/2
- Northwestern University, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- Northwestern, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
ReclutantFase 1
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Reclutant
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutantFase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Assaigs de Síndromes mielodisplàsiques en altres ciutats
- Houston, TX43 estudis
- Baldwin Park, CA26 estudis
- New York City, NY21 estudis
- Seattle, WA21 estudis
- Washington, DC20 estudis
- Boston, MA19 estudis
- Tampa, FL19 estudis
- Miami, FL17 estudis
- Columbus, OH14 estudis
- Durham, NC14 estudis
- Atlanta, GA13 estudis
- St. Louis, MO13 estudis
Altres estudis a Chicago
- Càncer de pulmó de cèl·lules no petites61 estudis
- Càncer de mama58 estudis
- Càncer (tots els tipus)51 estudis
- Càncer metastàtic45 estudis
- Càncer de pròstata45 estudis
- Obesitat41 estudis
- Càncer de pulmó41 estudis
- Càncer d'ovari36 estudis
- Ictus34 estudis
- Càncer colorrectal33 estudis
- Insuficiència cardíaca31 estudis
- Sobrepès28 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.